Oragenics: Starting Public
This article was originally published in Start Up
Executive Summary
Oragenics opted for an IPO when VC backing failed to materialize, landing enough cash to advance its varied programs. Managing a public start-up in the Sarbanes-Oxley era has been a challenge for the Florida biotech, whose lead product is a genetically modified bacteria aimed at eliminating dental cavities.